乳腺癌放疗急性毒性远程监测系统:基于电子患者报告结局的研发与试点实施
研究开发并试点实施基于电子患者报告结局(ePRO)的乳腺癌放疗急性毒性远程评估与管理体系,在放疗期间及放疗后8周每周发送评估。678例患者中489例(72%)完成2607次评估(45%),419例应答者(86%;95%CI 82%-89%)报告中度及以上毒性;139例患者共264次评估触发严重毒性警报,其中83%发生在治疗结束后。
要点
- 678例患者中489例(72%)完成2607次评估(45%),应答者中86%报告中度及以上毒性。
- 139例患者共264次评估触发严重毒性警报,其中83%发生在放疗结束后。
- 治疗后触发警报的评估比例(13%)显著高于治疗期间(5%)(P < .001)。
核心结论
- 多数毒性发生在乳腺癌放疗结束后,基于ePRO的远程症状监测可填补临床实践空白,尤其适用于接受较短疗程放疗的患者。
研究设计与样本
- 2019年6月至2020年7月,对接受乳腺癌放疗的患者每周发放基于常见不良事件评价标准(CTCAE)的ePRO毒性评估,放疗期间及放疗后8周内进行。
- 共纳入678例患者,发送5787次评估;对部分患者和照护团队成员在随访时进行质性访谈(15次)。
主要发现
- 489例患者(72%)完成2607次评估(45%)。
- 419例应答者(86%;95%CI 82%-89%)报告中度及以上毒性。
- 139例患者共264次评估触发严重毒性临床警报,其中83%发生在治疗结束后。
- 治疗后触发警报的评估比例(219次[13%])显著高于治疗期间(45次[5%])(P < .001)。
- 部分乳腺照射患者治疗后评估完成率高于全乳切除术后放疗患者(发生率比0.70;95%CI 0.60-0.81)(P < .001),尽管前者严重毒性更少。
临床怎么用
- 远程ePRO监测可捕捉放疗结束后出现的急性毒性,弥补常规门诊随访的不足。
- 应做好患者引导,说明ePRO的目的是辅助临床照护而非仅用于研究。
局限性
- 评估完成率仅45%,存在数据不完整。
- 需要进一步研究ePRO相关成本能否通过减少常规门诊随访来抵消,以及该方法的可接受性和适宜性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to develop and study the implementation of a remote system for toxicity assessment and management of acute side effects of breast radiation using electronic patient-reported outcomes (ePROs). METHODS AND MATERIALS: A response-adapted Patient-Reported Outcomes Common Terminology Criteria for Adverse Events-based assessment for breast radiation toxicity was administered weekly during and for 8 weeks after radiation from June 2019 to July 2020. The care team received alerts when "severe" symptoms were reported by patients, who were then contacted. Treatment, clinic, and sociodemographic characteristics were abstracted from patient records. A subsample of patients and care team members was qualitatively interviewed at follow-up. RESULTS: Overall, 5787 assessments were sent to 678 patients, of whom 489 (72%) completed 2607 assessments (45%). Moderate or greater toxicity was reported by 419 responders (86%; 95% CI, 82%-89%). Clinician alerts for severe toxicity were generated for 264 assessments among 139 unique patients, of which 83% occurred posttreatment. The proportion of surveys that prompted an alert was significantly higher after treatment (219 [13%]) than during treatment (45 [5%]) (P < .001). Survey completion rates in the posttreatment period were higher among patients undergoing partial breast irradiation than postmastectomy radiation (incidence rate ratio, 0.70; 95% CI, 0.60-0.81) (P < .001) despite these patients experiencing less severe toxicity. Interviews (15) found that patients had a positive experience with ePROs, although many thought the primary purpose was for research rather than symptom management. CONCLUSIONS: With the majority of toxicity occurring after breast radiation has ended, remote symptom monitoring with ePROs appears to fill a gap in clinical practice, particularly for patients undergoing shorter courses of radiation. It is important to properly onboard patients and explain that the purpose of ePROs is to aid clinical care. Further research is needed to determine whether the costs associated with ePROs can be offset by reducing routine clinic visits and whether this approach is acceptable and appropriate.
引用
- Lapen K, Sabol C, Tin AL, et al. Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34314814. doi:10.1016/j.ijrobp.2021.07.1692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。